Vir Biotechnology logo

Vir BiotechnologyNASDAQ: VIR

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

11 October 2019

Next earnings report:

21 February 2025

Last dividends:

N/A

Next dividends:

N/A
$951.65 M
-86%vs. 3y high
73%vs. sector
-vs. 3y high
-vs. sector
-90%vs. 3y high
34%vs. sector
-62%vs. 3y high
83%vs. sector

Price

after hours | 4 min ago
$6.91-$0.04(-0.58%)

Dividend

No data over the past 3 years
$289.00 K$8.14 M
$289.00 K-$213.72 M

Analysts recommendations

Institutional Ownership

VIR Latest News

Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency
businesswire.com18 November 2024 Sentiment: POSITIVE

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP), has issued a positive opinion on the application for orphan drug designation of tobevibart and elebsiran for the treatment of chronic hepatitis delta (CHD). This opinion is based on encouraging preliminary data from the Phase 2 SOLSTICE trial. Vir Biotechnology will present 24-week data from the Phase 2 SOLSTICE trial at A.

Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting
businesswire.com15 November 2024 Sentiment: POSITIVE

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced end-of-treatment data from Part B of the MARCH Phase 2 clinical study evaluating combinations of tobevibart and elebsiran, with or without pegylated interferon alfa (PEG-IFNα), in participants with chronic hepatitis B. The study demonstrated promising rates of hepatitis B surface antigen (HBsAg) loss (seroclearance) in participants with low baseline HBsAg (

Vir Biotechnology, Inc. (VIR) Q3 2024 Earnings Call Transcript
seekingalpha.com31 October 2024 Sentiment: POSITIVE

Vir Biotechnology, Inc. (NASDAQ:VIR ) Q3 2024 Earnings Conference Call October 31, 2024 4:30 PM ET Company Participants Richard Lepke - Senior Director, Investor Relations Marianne De Backer - Chief Executive Officer Mark Eisner - Executive Vice President & Chief Medical Officer Jason O'Byrne - Executive Vice President & Chief Financial Officer Conference Call Participants Paul Choi - Goldman Sachs Eric Joseph - JPMorgan Mike Ulz - Morgan Stanley Gena Wang - Barclays Alec Stranahan - Bank of America Nikola Gasic - Leerink Phil Nadeau - TD Cowen Patrick Trucchio - H.C. Wainwright & Co.

Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024
businesswire.com17 October 2024 Sentiment: NEUTRAL

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2024, on October 31, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on October 31, 2024. The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors.

Prediction: This Pharma Stock Will Be the Best Performer the Rest of 2024
247wallst.com06 August 2024 Sentiment: POSITIVE

24/7 Wall St. Insights Market pullbacks can make nervous investors leery of investing in industries that are speculative in nature.

Bullish On Vir Biotechnology's Innovative Pipeline That Targets HIV And Hepatitis
seekingalpha.com17 July 2024 Sentiment: POSITIVE

VIR develops medicines for infectious and viral diseases using proprietary platforms for monoclonal antibodies and T cell-based Viral Vectors. Positive Phase 2 trial results for chronic hepatitis delta highlight the company's potential to address unmet medical needs. Strategic collaborations include the Bill & Melinda Gates Foundation, Alnylam Pharmaceuticals, and Gilead Sciences.

Vir Biotechnology (VIR) Up on Positive Data From HDV Study
zacks.com06 June 2024 Sentiment: POSITIVE

Vir Biotechnology (VIR) rises on upbeat data from its phase II study evaluating tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta.

Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer
businesswire.com29 May 2024 Sentiment: POSITIVE

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Mark D. Eisner, M.D., M.P.H. will join the company as Executive Vice President and Chief Medical Officer (CMO), effective June 03, 2024. Dr. Eisner will be a part of the company's Executive Management Team and will report directly to Marianne De Backer, M.Sc., Ph.D., MBA, Vir's Chief Executive Officer. Dr. Eisner comes from Sonoma Biotherapeutics, Inc., where he most recently held the position of CMO. In.

Multiple Abstracts Highlighting Vir Biotechnology's Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024
businesswire.com22 May 2024 Sentiment: POSITIVE

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting new data from the Company's chronic hepatitis delta and chronic hepatitis B programs have been accepted for presentation at the annual meeting of the European Association for the Study of the Liver, EASL™ Congress 2024, taking place in Milan, Italy from June 5-8. This includes an oral presentation on June 8, which was originally accepted as a late-breaker poster, that will hig.

Vir Biotechnology, Inc. (VIR) Q1 2024 Earnings Call Transcript
Seeking Alpha03 May 2024 Sentiment: NEUTRAL

Vir Biotechnology, Inc. (NASDAQ: VIR) Q1 2024 Earnings Conference Call on May 2, 2024 at 4:30 PM ET featured company executives Sasha Damouni Ellis, Marianne De Backer, Carrie Huang, and Sung Lee. Conference call participants included Gena Wang, Paul Choi, Alec Stranahan, Phil Nadeau, Patrick Trucchio, Rosa Chen, Joseph Stringer, Eric Joseph, and Michaels Ulz. The call was moderated by the operator who greeted everyone.

  • 1(current)

What type of business is Vir Biotechnology?

Vir Biotechnology, Inc. is an American clinical immunology company. Registered in 2016 in the state of Delaware. Headquarters are located in San Francisco, California. The company specializes in developing methods based on a combination of immune responses and advanced technologies for the treatment and prevention of serious diseases such as hepatitis B or HBV, influenza A, severe acute respiratory syndrome, coronavirus 2 or SARS-CoV-2, human immunodeficiency virus or HIV, and tuberculosis. Drug candidates are developed on four technological platforms focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or miRNA, through internal development, collaborations, and acquisitions.

What sector is Vir Biotechnology in?

Vir Biotechnology is in the Healthcare sector

What industry is Vir Biotechnology in?

Vir Biotechnology is in the Biotechnology industry

What country is Vir Biotechnology from?

Vir Biotechnology is headquartered in United States

When did Vir Biotechnology go public?

Vir Biotechnology initial public offering (IPO) was on 11 October 2019

What is Vir Biotechnology website?

https://www.vir.bio

Is Vir Biotechnology in the S&P 500?

No, Vir Biotechnology is not included in the S&P 500 index

Is Vir Biotechnology in the NASDAQ 100?

No, Vir Biotechnology is not included in the NASDAQ 100 index

Is Vir Biotechnology in the Dow Jones?

No, Vir Biotechnology is not included in the Dow Jones index

When was Vir Biotechnology the previous earnings report?

No data

When does Vir Biotechnology earnings report?

The next expected earnings date for Vir Biotechnology is 21 February 2025